for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ABIOMED, Inc.

ABMD.OQ

Latest Trade

169.64USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

155.23

 - 

427.42

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
169.64
Open
--
Volume
--
3M AVG Volume
13.40
Today's High
--
Today's Low
--
52 Week High
427.42
52 Week Low
155.23
Shares Out (MIL)
45.38
Market Cap (MIL)
7,697.71
Forward P/E
32.98
Dividend (Yield %)
--

Next Event

Q2 2020 Abiomed Inc Earnings Call

Latest Developments

More

Abiomed Receives FDA PMA Approval For Impella 5.5 With SmartAssist

Abiomed Says Highest Court In Germany Affirms Strength Of Its Patents

Abiomed Comments On Centers For Medicare & Medicaid Services Final Rule For Inpatient Prospective Payment System

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ABIOMED, Inc.

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Industry

Medical Equipment & Supplies

Contact Info

22 CHERRY HILL DR

+1.978.7775410

http://www.abiomed.com/

Executive Leadership

Michael R. Minogue

Chairman of the Board, President, Chief Executive Officer

Todd A. Trapp

Chief Financial Officer, Vice President

David M. Weber

Chief Operating Officer

Ian McLeod

Vice President, Corporate Controller

Michael G. Howley

Vice President, General Manager - Global Sales and Marketing

Key Stats

1.89 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.4K

2018

0.6K

2019

0.8K

2020(E)

0.9K
EPS (USD)

2017

1.170

2018

2.450

2019

5.100

2020(E)

5.144
Price To Earnings (TTM)
30.34
Price To Sales (TTM)
9.66
Price To Book (MRQ)
7.68
Price To Cash Flow (TTM)
28.16
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
29.30
Return on Equity (TTM)
26.62

Latest News

Latest News

BRIEF-Abiomed Q4 GAAP EPS $0.80

* ABIOMED ANNOUNCES Q4 FY 2018 REVENUE OF $174 MILLION, UP 40%, AND TOTAL YEAR REVENUE OF $594 MILLION, UP 33%, OVER PRIOR YEAR

BRIEF-Abiomed Reports Q4 GAAP Earnings Per Share $0.80

* ABIOMED ANNOUNCES Q4 FY 2018 REVENUE OF $174 MILLION, UP 40%, AND TOTAL YEAR REVENUE OF $594 MILLION, UP 33%, OVER PRIOR YEAR

BRIEF-Abiomed Announces European Approval For Impella 5.5(Tm)

* ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5(TM) AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG Source text for Eikon: Further company coverage:

BRIEF-Abiomed Announces European Approval (CE Marking) For Impella 5.5™

* ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5™ AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Abiomed Receives FDA Approval For Impella Cp® With Smartassist™ And Optical Sensor

* ABIOMED RECEIVES FDA APPROVAL FOR IMPELLA CP® WITH SMARTASSIST™ AND OPTICAL SENSOR

BRIEF-Abiomed To Appoint Todd Trapp Chief Financial Officer

* ABIOMED TO APPOINT NEW CHIEF FINANCIAL OFFICER TODD A. TRAPP

Abiomed to pay $3.1 million to settle case over lavish doctor meals

Abiomed Inc has agreed to pay $3.1 million to resolve a U.S. probe into allegations that it sought to get doctors to use a line of heart pumps it produced by buying them lavish meals at some of the most expensive restaurants in the United States.

BRIEF-Abiomed Says Entered Settlement With U.S. DoJ Resolving Claims Related To Employee Meals

* ABIOMED - ON MARCH 6, ENTERED SETTLEMENT WITH U.S. DOJ RESOLVING CLAIMS ON CO'S REIMBURSEMENT OF EMPLOYEE EXPENSES FOR MEALS WITH HEALTHCARE PROVIDERS Source text: (http://bit.ly/2G9t6b6) Further company coverage:

Heart pump maker Abiomed settles U.S. kickback probe for $3.1 mln

Abiomed Inc has agreed to pay $3.1 million to resolve a U.S. investigation into allegations that it sought to induce doctors into using a line of heart pumps it produced by buying them lavish meals.

BRIEF-Abiomed Receives Approval For Expanded FDA Indication For High Risk PCI Procedures

* ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR HIGH RISK PERCUTANEOUS CORONARY INTERVENTION (PCI) PROCEDURES Source text for Eikon: Further company coverage:

BRIEF-Abiomed Receives Approval For Expanded FDA Indication For Cardiomyopathy With Cardiogenic Shock

* ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR CARDIOMYOPATHY WITH CARDIOGENIC SHOCK

BRIEF-Abiomed Q3 Gaap Earnings Per Share $0.29

* ABIOMED ANNOUNCES Q3 FY 2018 RECORD REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR

BRIEF-Abiomed Reports Q3 Adjusted Earnings Per Share $0.70

* ABIOMED ANNOUNCES Q3 FY 2018 RECORD REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR

BRIEF-Abiomed Reports Preliminary Q3 FY 2018 Revenue Of $154 Mln, Up 34 Pct Over Prior Year

* ABIOMED ANNOUNCES PRELIMINARY Q3 FY 2018 REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR

BRIEF-Abiomed Q2 earnings per share $0.54

* Abiomed announces Q2 fy 2018 revenue of $132.8 million, up 29% and record u.s. Patient utilization, up 33 pct

Abiomed invests in Israeli medical device maker Magenta

Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc, a maker of catheter-based heart pumps, and venture capital firm Pitango.

BRIEF-Abiomed receives FDA PMA approval for Impella RP for right heart failure

* Abiomed receives FDA PMA approval for Impella RP for right heart failure Source text for Eikon: Further company coverage:

BRIEF-Abiomed maintains fiscal year 2018 revenue guidance

* Says is maintaining its fiscal year 2018 revenue guidance of $560 million to $575 million - SEC filing

BRIEF-ABIOMED says CFO Michael Tomsicek resigns

* ABIOMED announces resignation of chief financial officer and welcomes back former chief financial officer as consultant

BRIEF-Abiomed Q1 gaap earnings per share $0.82

* Abiomed announces Q1 FY 2018 revenue of $132.5 million, up 29% over prior year

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up